{"id":45285,"date":"2022-06-21T07:01:38","date_gmt":"2022-06-21T05:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/"},"modified":"2022-06-21T07:01:38","modified_gmt":"2022-06-21T05:01:38","slug":"igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/","title":{"rendered":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate"},"content":{"rendered":"
\n

BETHESDA, Md.–(BUSINESS WIRE)–#IGC<\/a>–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer\u2019s drug development candidate.\n<\/p>\n

<\/a><\/p>\n

\nResearchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (\u201cJNCASR\u201d), in India, conducted about 10 years of research and discovery work on NMI (Naphthalene Monoimide) compounds and the role of NMI compounds on neurotoxicity associated with Alzheimer\u2019s. Neurotoxicity, which can result from exposure to natural or synthetic substances, causes damage to the brain and the nervous system. In Alzheimer\u2019s patients, neurotoxicity is linked to beta amyloid (A\u03b2) plaques and Neuro Fibrillary Tangles (NFT).\n<\/p>\n

\nJNCASR\u2019s research based on Alzheimer\u2019s cell lines, identified one lead NMI molecule, TGR 63, with the potential to reduce beta amyloid (A\u03b2) plaques. Further, they demonstrated that the molecule reduces cognitive decline in a transgenic mouse model of Alzheimer\u2019s. Their results were published in Advanced Therapeutics<\/i> under the title \u201cNaphthalene Monoimide Derivative Ameliorates Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer\u2019s Disease\u201d on January 28, 2021.\n<\/p>\n

\nIGC acquired exclusive global rights to the molecule and plans to develop this NMI lead candidate further. IGC is currently in human trials with IGC-AD1 that targets neuropsychiatric symptoms associated with dementia in Alzheimer\u2019s. It is currently being evaluated as an Alzheimer\u2019s symptom modifying agent. TGR-63, the new molecule, strategically, gives the Company a potential disease modifying agent and positions the Company to develop a drug that can potentially treat or modify Alzheimer\u2019s by targeting beta amyloid (A\u03b2) plaques.\n<\/p>\n

\nAccording to the World Health Organization (2020), worldwide, about 55 million individuals suffer from dementia, and about 60-70% of dementia is related to Alzheimer\u2019s. This number is projected to increase to about 78 million individuals in 2030, with the estimated total global societal cost of dementia expected to surpass $2.8 trillion by 2030.\n<\/p>\n

\nAbout JNCASR:<\/b>\n<\/p>\n

\nJawaharlal Nehru Centre for Advanced Scientific Research, located in Bengaluru, India, is an autonomous institution under the Department of Science and Technology, Government of India. https:\/\/www.jncasr.ac.in\/home<\/a>\n<\/p>\n

\nAbout IGC:<\/b>\n<\/p>\n

\nIGC has two segments: Infrastructure and Life Sciences. The company is based in Maryland, U.S.A.\n<\/p>\n

\nForward-looking Statements:<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements. These forward-looking statements are based largely on IGC\u2019s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC\u2019s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company\u2019s failure or inability to commercialize one or more of the Company\u2019s products or technologies, including the product or formulation described in this release, or failure to obtain regulatory approval for the product or formulation, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA\u2019s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC\u2019s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Reports on Form 10-Q, filed with the SEC on August 11, 2021, and October 29, 2021, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nClaudia Grimaldi
\n
301-983-0998\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BETHESDA, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer\u2019s drug development candidate. Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (\u201cJNCASR\u201d), in India, conducted about 10 years of research and discovery work on NMI … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45285","6":"format-standard","7":"category-industry"},"yoast_head":"\nIGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BETHESDA, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer\u2019s drug development candidate. Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (\u201cJNCASR\u201d), in India, conducted about 10 years of research and discovery work on NMI ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T05:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate\",\"datePublished\":\"2022-06-21T05:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/\"},\"wordCount\":580,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005637\\\/en\\\/650703\\\/21\\\/IGC_New_Logo_High.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/\",\"name\":\"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005637\\\/en\\\/650703\\\/21\\\/IGC_New_Logo_High.jpg\",\"datePublished\":\"2022-06-21T05:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005637\\\/en\\\/650703\\\/21\\\/IGC_New_Logo_High.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005637\\\/en\\\/650703\\\/21\\\/IGC_New_Logo_High.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/","og_locale":"en_US","og_type":"article","og_title":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend","og_description":"BETHESDA, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer\u2019s drug development candidate. Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (\u201cJNCASR\u201d), in India, conducted about 10 years of research and discovery work on NMI ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-21T05:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate","datePublished":"2022-06-21T05:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/"},"wordCount":580,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/","url":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/","name":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg","datePublished":"2022-06-21T05:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220620005637\/en\/650703\/21\/IGC_New_Logo_High.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/igc-acquires-exclusive-rights-for-a-potential-alzheimers-drug-development-candidate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45285"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45285\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}